Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03605186
Other study ID # CEBD-CU-2018-07-08
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 2019
Est. completion date March 2020

Study information

Verified date February 2019
Source Cairo University
Contact Dina Y Essa, B.D.SC
Phone 00201008222298
Email dina.yousef@dentistry.cu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

oral mucositis is a painful situation that significantly affects patients' quality of life with the severe cases being associated with ulcerated mucosa and secondary infection which may lead to life-threatening sepsis.Chamomile infusion in cryotherapy was used to aid in reduction of chemotherapy induced mucositis and to enhance the effect of standard cryotherapy alone by its anti-inflammatory, antifungal and antibacterial effect. The occurrence of oral mucositis is a significant complication of chemotherapy with prevalence of up to 80% in pediatric patients.The study is to be conducted at the in and outpatient clinics at the Department of Pediatric Oncology, National Cancer Institute,Egypt. A Structured interview questionnaire sheet will be filled with personal, medical and dental history. Intraoral examination will be carried out using sterile latex gloves, masks, plain mouth mirrors, sterile gauze and wooden tongue depressor. Patients who will agree to participate in the study will watch a video explaining how to perform oral hygiene.Preparation of the interventions is done in the clinic with 400 ml of distilled water with or without the infusion of 10 g of chamomile flowers."Chamomile classic infusion, Royal Herbs" .Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session. Follow ups are done at the 8th,15th and the 21st day of interventions application.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 2020
Est. primary completion date June 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria:

1. Patients with healthy and intact oral mucosa.

2. Patients diagnosed with bone tumor (osteosarcoma) for the first time.

3. Patients receiving Methotrexate as part of their chemotherapeutic regimen.

4. Both male and female patients undergoing chemotherapy at In and Out patient units of Pediatric Oncology department.

5. Age of patient ranging (6- 18) years old.

6. Legal representatives of patient must be able to read, understand and provide informed consent to participate in the trial.

7. Patients with no history of dental discomfort related to cold or hot food or beverage intake.

Exclusion Criteria:

1. Administration of antiviral or antifungal therapy and/or any other treatment for oral mucositis before enrollment in the study.

2. Presence of advanced or severe periodontitis (pocket depth more than 6mm).

3. Patients who were supposed to receive head and neck radiotherapy as part of their treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Chamomile oral cryotherapy
The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
Oral cryotherapy
The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.

Locations

Country Name City State
Egypt National Cancer Institute Cairo

Sponsors (2)

Lead Sponsor Collaborator
Cairo University National Cancer Institute, Egypt

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in "patient-reported oral mucositis". Primary outcome is measured using Children International Mucostitis Evaluation Scale (CHIMES).ChIMES1-4 each received a score of 0-5 where 5 is the worst degree of symptoms. ChIMES5 and ChIMES6 received a score of 1 or 0 if the child had received pain medications or not. Finally, ChIMES7 received a score of 1or 0 if oral ulcers were present or not. Any question that was scored as missing or 'I can't tell' was excluded from the total possible score. If all the questions were answered, the maximum score was 23. The ChIMES Total Score was the sum of all scores; 'I can't tell' responses and missing responses both received a score of 0. The ChIMES Percentage Score was the ChIMES Total Score over the total maximum score taking into account 'I can't tell' responses (by subtracting these items from the maximum score) multiplied by 100. Higher values indicate a worse outcome. Assessed at the 8th, 15th and the 21st day after application of the interventions.
Secondary Change in "Clinical assessment of oral mucositis". Assessed using Oral Mucositis World Health Organization Toxicity Scale.It represents grades of oral mucositis ranging from 0-4 with higher grades indicating worse outcome. Assessed at the 8th,15th and the 21st day after application of the interventions.
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03613389 - Prevention of Oral Mucositis After Using Oral Topical Vitamin E Versus Voriconazole and Levofloxacin in Pediatric Cancer Patients Receiving Chemotherapy N/A
Active, not recruiting NCT03972527 - Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients N/A